Results 121 to 130 of about 2,882,240 (203)

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Pharmacogenomics and Personalized Medicine, 2022
Fengting Yu,1,2,* Qun Li,1,2,* Linghang Wang,1,2 Hongxin Zhao,1,2 Hao Wu,3 Siyuan Yang,1,2 Yunxia Tang,1,2 Jiang Xiao,1,2 Fujie Zhang1,2 1Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Clinical Center ...
Yu F, Li Q, Wang L, Zhao H, Wu H, Yang S, Tang Y, Xiao J, Zhang F   +8 more
doaj  

Mutagenesis of Lysines 156 and 159 in Human Immunodeficiency Virus Type 1 Integrase (IN) Reveals Differential Interactions between these Residues and Different IN Inhibitors

Natural Product Communications, 2015
Human immunodeficiency virus (HIV) type 1 integrase (IN) active site, and viral DNA-binding residues K156 and K159 are predicted to interact both with strand transfer-selective IN inhibitors (STI), e.g. L-731,988, Elvitegravir (EVG), and the FDA-approved
David C. Crosby, Xiangyang Lei, Charles G. Gibbs, Manfred G. Reinecke, W. Edward Robinson   +4 more
doaj   +1 more source

Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents

Pediatric Health, Medicine and Therapeutics, 2013
James Nuttall,1 Tammy Meyers,2 Brian Eley11Paediatric Infectious Diseases Unit, Red Cross War Memorial Children's Hospital and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa; 2Department of Paediatrics ...
Nuttall J, Meyers T, Eley B
doaj  

Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy over the period 2017–2023

Journal of Global Antimicrobial Resistance
: Objective: We evaluated the prevalence of HIV-1 drug resistance in newly diagnosed individuals from 2017 to 2023, in Italy. Methods: Transmitted drug resistance (TDR) was evaluated by using the HIVdb algorithm (https://hivdb.stanford.edu/), through ...
A.C. Ka’e, F. Bassani, O. El Khalili, A. Bezenchek, F. Carli, A. Pupo, E. Gentilini Cacciola, L. Pezzati, L. Duca, I. Vicenti, W. Gennari, F. Lombardi, A. Shallvari, F. Saladini, V. Micheli, A. Cozzi-Lepri, A. Lai, M.M. Santoro, S. Rusconi   +18 more
doaj   +1 more source

Development and application of non-integrating lentiviral vectors for gene therapy [PDF]

, 2009
Lentiviruses stably integrate their genome into the host genome. Although this feature can be advantageous for long term transgene expression, it also has the potential to cause mutagenesis and cell transformation.
Apolonia, L.F.S.
core  

Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting

, 2019
To evaluate the durability of three integrase strand transfer inhibitors (INSTIs) and two NRTIs in ART-naive ...
Lo Caputo, Sergio, Cingolani A, Caramello P, Segala D, Cecchetto M, Nunnari G, Angarano G, Bandera A, Quiros Roldan E, Sangiovanni V, Quartu S, Minardi C, Girardi E, Starnini G, Maggiolo F, Cacopardo B, Di Martino F, Cattelan AM, Cascio A, Fontana Del Vecchio R, Costantini, Andrea, Marinello S, Andreoni M, Di Perri G, Chiodera A, Madeddu G, Baldelli F, Barocci V, von Schloesser F, Sarmati L, Gentile I, Tavelli A, Suardi C, Celesia B, Maddaloni L, Ialungo A., Bassetti M, Pellicanò G, Cristaudo A, Rossotti R, Londero A, Mazzotta, Valentina, Carletti F, Di Caro A, Ursitti MA, Plazzi MM, Acinapura R, Lazzarin A, Saracino A, Antinori, Andrea, Capetti A, Antinori A, Nozza S, Di Biagio, Antonio, Tincati C, Cozzi-Lepri A, Viale P, Iaiani G, Pellizzer G, Castagna A, Sighinolfi L, Falasca K, Bai F, d'Arminio Monforte, Antonella, Bagella P, Di Biagio A, Ippolito G, Blanc P, Cicalini S, Fanti I, Rodanò' A, Lo Caputo S, Monno L, Bobbio N, Fabrizio C, Molteni C, Capozzi M, Bonora S, Puzzolante C, Di Giuli C, Giacometti A, Menzaghi B, Mazzarello G, Truffa S, Magnani G, Marchetti GC, Moioli MC, Orofino GC, Gianotti N, Cinque P, Iardino R, Parruti G, Rusconi S, Milini P, Savinelli S, Sciandra M, Rivano Capparucia M, Galli M, De Luca A, Rezza G, Galli L, Cassola G, Gagliardini R, Verucchi G, Colomba C, Castelnuovo F, Rizzardini G, Puoti M, Gianotti, Nicola, Prota G, Vergori A, Marchetti, Giulia, Guaraldi G, Mondi A, Castelli F, Lorenzotti S, Perno CF, Francisci D, Borderi M, Santoro MM, Sozio F, Costantini A, Cauda R, Vullo V, Pinnetti C, Cozzi-Lepri, Alessandro, Capobianchi MR, Esposito V, Graziano S, Ceccherini-Silberstein F, Marchetti G, Pan A, Castagna, Antonella, Viscoli C, Macchia M, Carrara S, Viviani F, Abeli C, Bonfanti P, Lorenzini P, Gori A, Alessandrini A, Rusconi, Stefano, Ridolfo AL, Baldin G, Latini A, Borgia G, Schiaroli E, d'Arminio Monforte A, Salpietro S, Pozzetto I, Mazzarello, Giovanni, Donati V, Calcagno A, Lapadula G, Vecchiet J, Balotta C, Piolini R, Migliorino C, Mussini C, Rossetti B, Manfrin V, Lichtner M, Petrone F, Franco A, Vichi F   +165 more
core   +1 more source

HIV-1 Integrase Drug Discovery Comes of Age

, 2014
Insertion of the viral genome into host cell chromatin is a pivotal step in the replication cycle of the human immunodeficiency virus and other retroviruses.
Zeger Debyser, Demeulemeester, Jonas, Debyser, Zeger, Marc De Maeyer, De Maeyer, Marc, Jonas Demeulemeester   +5 more
core   +1 more source

HIV-1 Genetic Diversity and Transmitted Resistance to Integrase Strand Transfer Inhibitors in Benguela, Angola

Microorganisms
Angola is one of the countries with the highest HIV-1 genetic diversity, yet the implications of this diversity for antiretroviral therapy remain insufficiently characterised. Following the introduction of dolutegravir (DTG) in Angola in 2021, evaluating
Isabel S. Godinho, Gonçalo Queirós, Lesya Yefimenko, Filomena M. Pereira, João Piedade   +4 more
doaj   +1 more source

Patterns of HIV-1 Drug Resistance Observed Through Geospatial Analysis of Routine Diagnostic Testing in KwaZulu-Natal, South Africa

Viruses
HIV-1 drug resistance (HIVDR) impedes treatment and control of HIV-1, especially in high-prevalence settings such as KwaZulu-Natal (KZN) province, South Africa.
Lilishia Gounder, Aabida Khan, Justen Manasa, Richard Lessells, Andrew Tomita, Melendhran Pillay, Sontaga C. Manyana, Subitha Govender, Kerri-Lee Francois, Pravi Moodley, Nokukhanya Msomi, Kerusha Govender, Raveen Parboosing, Sikhulile Moyo, Kogieleum Naidoo, Benjamin Chimukangara   +15 more
doaj   +1 more source

Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in

, 2016
Objectives: Integrase strand transfer inhibitor (INSTI) is a new class of antiretroviral (ARV) drugs designed to block the action of the integrase viral enzyme, which is responsible for insertation of the HIV-1 genome into the host DNA. The aim of this study was to evaluate for the first time INSTI resistance mutations in Turkish patients.
Sayan, M, Gunduz, A, Ersoz, G, Inan, A, Deveci, A, Ozgur, G, Sargin, F, Karagoz, G, Inci, A, Inan, D, Ulcay, A, Karaoglan, I, Kaya, S, Kutlu, SS, Suer, K, Cagatay, A, Akalin, H   +16 more
openaire   +2 more sources